Matthias Heinzel, CEO of life science at Merck KGaA
November 16, 2022 02:47 PM EST
Pharma
Manufacturing

Mer­ck KGaA’s Mil­li­pore­Sig­ma in­vests $286M to build out biosafe­ty test­ing

Tyler Patchen

News Reporter

Mil­li­pore­Sig­ma, the US and Cana­di­an life sci­ence di­vi­sion of Mer­ck KGaA, is plunk­ing down al­most $300 mil­lion to boost biosafe­ty test­ing in the US. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times